Project Grant R01AR086871
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $312K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75246, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The University of Texas Southwestern Medical Center $613,036 on August 1, 2026, for investigator-initiated research under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project, "Leveraging Lymphatics to Reverse Heterotopic Ossification," addresses the pathologic formation of extra-skeletal bone occurring in approximately twenty percent of patients following hip...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Brigham & Women's Hospital Inc. $683,016 on May 8, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the role of HOX genes in musculo-skeletal development using human induced pluripotent stem cell (IPS)–derived in vitro models. The research employs human IPS-based cell culture systems to study HOX gene function during skeletal muscle and motoneuron...
- The National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Texas A&M University System Health Science Center $114,073 on September 23, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds investigation of sympathetic signaling as a mechanism underlying bone loss following spinal cord injury. The research comprises two aims: determining spinal-cord-injury-level-dependent effects of...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The University of Texas Health Science Center at San Antonio $496,963 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the osteocyte interactome's role in bone mechanotransduction and osteogenesis. The research elucidates how osteocytes—the primary mechanosensory cells in bone—coordinate bone remodeling through a...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $676,210 to The Washington University on August 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient will conduct research into DNMT3A as an epigenetic transcriptional therapeutic target in femoroacetabular impingement (FAI) progression to osteoarthritis. FAI is a pre-arthritic hip condition affecting individuals aged 20 to 40; standard surgical treatment...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Baylor College of Medicine $374,000 on August 17, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the role of the transcription factor TONEBP/NFAT5 in regulating chondrocyte energy availability and extracellular matrix synthesis during postnatal bone growth. The research examines how chondrocytes balance intense matrix production with protein quality...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Oregon $343,491 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to engineer hemoglobin-based oxygen-carrying spheroids that enhance the viability and secretome activity of injectable mesenchymal stem cells in hypoxic osteoarthritis joint environments. The recipient will develop functional hemoglobin...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Texas Health Science Center at Houston $156,000 on July 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project investigates pulmonary arterial hypertension susceptibility in systemic sclerosis patients carrying the DNASE1L3 R206C genetic variant. Aim 1 will assess the impact of chronic DNASE1L3 deficiency on the pulmonary vasculature in mice...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $129,330 on September 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate molecular and physiological regulation of mRNA trafficking and translation in osteocyte dendrites. The project examines how osteocytes regulate gene and protein expression with...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Texas Health Science Center at Houston $623,286 on July 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate hypoxia-driven NUDT21-mediated alternative polyadenylation in lung and skin fibrosis associated with systemic sclerosis. The project, designated R01AR087804, examines how tissue hypoxia—driven by Raynaud's phenomenon and...